NAD+ IV Infusion

Safety Profile of NAD+ IV Infusion

Evidence Limitation: The available evidence for NAD+ IV infusion safety is extremely limited. Only one small retrospective pilot study specifically examined IV NAD+ tolerability, and no large-scale clinical trials have assessed safety outcomes.

Known Side Effects

Based on the single retrospective tolerability study available:

• The pilot study examined tolerability in a "real-world setting" but specific adverse events are not detailed in the evidence provided
• No serious adverse events or safety signals are explicitly reported in the available abstracts
• Evidence is very thin - conclusions about side effects cannot be drawn from this limited data

Contraindications

No established contraindications are identified in the available evidence. This represents a significant knowledge gap, as formal contraindication profiles have not been systematically studied.

Drug Interactions

No drug interactions are documented in the provided evidence. The absence of interaction data does not mean interactions don't exist - this area requires further investigation.

High-Risk Populations

The evidence does not identify specific populations that should avoid NAD+ IV infusion. However, given the limited safety data, the following considerations apply:

• Pregnant and breastfeeding women: No safety data available
• Children: No pediatric safety data identified
• Patients with kidney disease: While one study examined NAD+ metabolites in CKD patients, it did not specifically assess IV NAD+ safety in this population
• Patients with liver impairment: No specific safety data available

Critical Safety Gaps

The evidence reveals substantial gaps in safety knowledge:

• No dose-ranging safety studies
• No long-term safety data
• No systematic adverse event reporting
• No pharmacovigilance data from clinical use
• No safety data in vulnerable populations

Clinical Disclaimer: This information is for educational purposes only and should not replace consultation with a healthcare provider. Given the limited safety data available, patients considering NAD+ IV infusion should discuss potential risks and benefits with their physician, particularly if they have underlying health conditions or take medications.

Conservative Recommendation: The thin evidence base suggests extreme caution is warranted until more comprehensive safety studies are completed.